Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection

By LabMedica International staff writers
Posted on 25 Jul 2025

Prostate cancer can be difficult to detect early, limiting timely and appropriate treatment. More...

While calcification—calcium build-up in soft tissues—has previously been suggested as a possible indicator, it remains underexplored. Diagnosing the disease accurately and quickly is essential to improving patient outcomes and reducing the need for invasive treatments such as surgery. Researchers have now found that certain chemical elements within calcifications appear to be linked to how aggressive the cancer is. Analyzing the chemical composition of these calcifications could provide new markers to help doctors identify the disease sooner.

The research team at Keele University (Keele, EN, UK; www.keele.ac.uk) had previously demonstrated that calcifications could signal prostate cancer. In their latest study, the researchers expanded on that work by analyzing their chemical composition. To do this, researchers used the Diamond Light Source synchrotron in Oxford to examine calcified prostate tissue at a highly detailed level. Their investigation focused on identifying the elements present within the calcifications and exploring whether any correlations existed with tumor severity.

In their study published in ACS Chemical & Biomedical Imaging - Bioimaging of Metals, the researchers reported that elements such as iron, copper, nickel, manganese, and chromium were associated with the tumor’s Grade Group classification. These findings indicate that the presence of certain elements could serve as early warning signs of cancer aggression. The simplicity of detecting such markers could eventually lead to personalized treatment plans and reduce reliance on invasive interventions. The researchers plan to build on this discovery by developing new diagnostic markers based on elemental analysis of prostate tissue, aiming to detect cancer earlier and help doctors determine the most appropriate treatment path for each patient.

“For the first time in prostate tissue, we’ve been able to look closely at what these tiny calcium deposits are made of, and we’ve found that certain elements seem to be linked to how aggressive the cancer is. That’s really exciting because it means we might be able to use these elements as early warning signs,” said Dr. Charlene Greenwood, co-lead author of the study. “The hope is that this research will lead to better ways to spot prostate cancer earlier and help doctors decide on the best treatment for each patient, potentially avoiding more invasive procedures.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Manual Pipetting Aid
Pipette Controllers macro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.